Nguyen David-Dan, Nguyen Anna-Lisa, Murayama Anju, Kaushal Sanchit, Bernardino Rui, Wettstein Marian S, Satkunasivam Raj, Trinh Quoc-Dien, Kulkarni Girish S, Marshall Deborah C, Wallis Christopher J D
Department of Surgery, Division of Urology, University of Toronto, Toronto, Ontario, Canada.
Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Urol Pract. 2025 Jul;12(4):401-407. doi: 10.1097/UPJ.0000000000000814. Epub 2025 Mar 18.
This study aims to characterize payments by drug and medical device manufacturers to current program directors (PDs) of the Society of Urologic Oncology (SUO)-accredited fellowship programs in the United States.
PDs were identified from SUO fellowship websites as of February 2024. Demographic data, educational background, and scholarly metrics were collected through an online search. Industry payments to SUO PDs from 2014 to 2023 were extracted from the Open Payments database. Descriptive statistics were used to summarize PD characteristics and industry payment details. Univariable linear regression was used to assess the association of PD characteristics or scholarly metrics with payments.
Fifty-one PDs from 37 SUO fellowship programs were identified. PDs were predominantly men (94%) and mid career. In aggregate, over the study period, PDs received US dollars ($) 18,963,555 in industry payments over 10 years. Most payments were for associated research funding ($15,490,525, 81.6%; median [IQR] per PD recipient, $126,584 [$36,565-$706,516]; 1262 payments). General payments accounted for a total of $3,473,030 (18.3%; median [IQR] per PD, $10,345 [$2196-$49,180]). SUO PDs received $120,763 (0.6%) for education fees. No association was found between PD characteristics or research metrics and industry payments.
PDs of SUO fellowships receive significant industry payments, surpassing those received by the average urologist. Most of these payments are allocated to research, with smaller proportions directed to general support and educational initiatives.
本研究旨在描述美国泌尿肿瘤学会（SUO）认证的 fellowship 项目现任项目主任（PD）从药品和医疗器械制造商处获得的报酬情况。
截至2024年2月，从SUO fellowship网站上识别出项目主任。通过在线搜索收集人口统计学数据、教育背景和学术指标。从公开支付数据库中提取2014年至2023年行业向SUO项目主任的支付情况。使用描述性统计来总结项目主任的特征和行业支付细节。采用单变量线性回归来评估项目主任特征或学术指标与支付之间的关联。
确定了来自37个SUO fellowship项目的51名项目主任。项目主任以男性为主（94%），处于职业生涯中期。总体而言，在研究期间，项目主任在10年内共获得行业支付18,963,555美元。大部分支付用于相关研究资金（15,490,525美元，81.6%；每位项目主任接收者的中位数[四分位间距]为126,584美元[36,565美元 - 706,516美元]；1262笔支付）。一般支付总计3,473,030美元（18.3%；每位项目主任的中位数[四分位间距]为10,345美元[2196美元 - 49,180美元]）。SUO项目主任获得教育费用120,763美元（0.6%）。未发现项目主任特征或研究指标与行业支付之间存在关联。
SUO fellowship项目的项目主任获得了大量行业支付，超过了普通泌尿科医生的收入。这些支付大部分分配给了研究，分配给一般支持和教育项目的比例较小。
